

UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/039,947	10/25/2001	Robert C. Moore	SD6858	8459
7590 11/06/2003			EXAMINER	
Timothy D. Stanley			CINTINS, IVARS C	
Sandia National Laboratories P.O. Box 5800 - MS-0161 Albuquerque, NM 87185-0161			ART UNIT	PAPER NUMBER
			1724	
		•	DATE MAILED: 11/06/200	3

Please find below and/or attached an Office communication concerning this application or proceeding.

		A-S				
	Application No.	Applicant(s)				
	10/039,947	MOORE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Ivars C. Cintins	1724				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may within the statutory minimum of tirill apply and will expire SIX (6) Mic cause the application to become	a reply be timely filed nirty (30) days will be considered timely. DNTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on						
	_ · s action is non-final.					
Since this application is in condition for allowal closed in accordance with the practice under the second se	nce except for formal m					
Disposition of Claims						
4) Claim(s) <u>1-49</u> is/are pending in the application						
4a) Of the above claim(s) is/are withdraw	vn from consideration.					
5) Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-49</u> are subject to restriction and/or e	election requirement.					
9)☐ The specification is objected to by the Examiner		•				
10) ☐ The drawing(s) filed on is/are: a) ☐ accep		the Examiner.				
Applicant may not request that any objection to the	•					
11) The proposed drawing correction filed on	is: a)☐ approved b)☐	disapproved by the Examiner.				
If approved, corrected drawings are required in rep	ly to this Office action.					
12)☐ The oath or declaration is objected to by the Exa	aminer.	·				
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C	. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:	,					
 Certified copies of the priority documents 	s have been received.					
2. Certified copies of the priority documents	have been received in	Application No				
 3. Copies of the certified copies of the prior application from the International Bur * See the attached detailed Office action for a list of the certified of the copies of the prior application. 	eau (PCT Rule 17.2(a))					
14)⊠ Acknowledgment is made of a claim for domestic	priority under 35 U.S.C	C. § 119(e) (to a provisional application).				
a) ☐ The translation of the foreign language pro- 15)☐ Acknowledgment is made of a claim for domestic	- •					
Attachment(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	· ===	v Summary (PTO-413) Paper No(s) f Informal Patent Application (PTO-152)				

Application/Control Number: 10/039,947

Art Unit: 1724

This application contains claims directed to the following patentably distinct treating agent species of the claimed invention:

- (1) magnesium hydroxide (including magnesium oxide which converts to magnesium hydroxide); and
 - (2) calcium hydroxide (including calcium oxide which converts to calcium hydroxide).

Applicant is required under 35 U.S.C. 121 to elect a single disclosed treating agent species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claims are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, Applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should Applicant traverse on the ground that the species are not patentably distinct, Applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 10/039,947

Art Unit: 1724

Any inquiry concerning this communication or earlier communications from the examiner should be directed to I. Cintins whose telephone number is (703) 308-3840. The examiner can normally be reached on Monday through Friday from 8:30 AM to 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Blaine Copenheaver, can be reached at (703) 308-1261.

The centralized facsimile number for the USPTO is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0661.

Ivars C. Cintins Primary Examiner Art Unit 1724

I. Cintins November 3, 2003